Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Liabilities and Shareholders Equity (2023 - 2025)

CG Oncology (CGON) has disclosed Liabilities and Shareholders Equity for 3 consecutive years, with $791.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 4.87% year-over-year to $791.6 million, compared with a TTM value of $3.0 billion through Dec 2025, up 20.42%, and an annual FY2025 reading of $791.6 million, up 4.87% over the prior year.
  • Liabilities and Shareholders Equity was $791.6 million for Q4 2025 at CG Oncology, up from $729.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $791.6 million in Q4 2025 and bottomed at $199.3 million in Q4 2023.
  • Average Liabilities and Shareholders Equity over 3 years is $622.3 million, with a median of $701.4 million recorded in 2025.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 278.72% in 2024, then increased 4.87% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $199.3 million in 2023, then surged by 278.72% to $754.8 million in 2024, then rose by 4.87% to $791.6 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for CGON at $791.6 million in Q4 2025, $729.9 million in Q3 2025, and $701.4 million in Q2 2025.